开放心脏手术后心周并发症的药理预防和治疗方法
Alireza Malektojari1,2, Rosa Tahmasebipour2,3, Maedeh Fadaeihosein3
1Evidence Based Medicine Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Heart (British Cardiac Society)
|January 23, 2025
概括
科尔奇辛有效地降低心脏手术后后心脏切除术后综合征的风险. 建议使用β-阻塞剂来预防心房动和心周炎,改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏外科手术后心周并发症很常见,并且会使人衰弱.
- 有效的预防和治疗策略对于患者的生存至关重要.
研究的目的:
- 确定心脏手术后心周并发症的最有效和最安全的干预措施.
- 通过网络元分析来比较各种治疗方法的疗效.
主要方法:
- 在PubMed/MEDLINE,EMBASE和Cochrane CENTRAL数据库中进行系统搜索.
- 包括39个随机对照试验,其中有6419名成年参与者.
- 频率主义随机效应网络元分析以总结使用相对风险和95%置信区间的干预效应.
主要成果:
- 胆固醇显著降低了心脏切除术后综合征的风险 (RR 0.53).
- 贝塔抑制剂在预防心房 (RR 0.4) 和术后心膜炎 (RR 0.66) 中表现出有效性.
- 鱼油,NSAIDs和胆固醇可以降低术后心房的风险.
结论:
- 强烈推使用科尔奇辛来预防心术后综合征.
- 建议使用β-抑制剂来减少术后心房动.
- 由于目前的证据不足,对其他干预措施还需要进一步的高质量研究.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
Heart Failure Drugs: Inotropic Agents
510
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
449
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
449
Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
706
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
706
Pathophysiology of Cardiac Performance
520
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
520


